{"id":"phentermine-topiramate-oral-product","safety":{"commonSideEffects":[{"rate":"15-25","effect":"Insomnia"},{"rate":"10-20","effect":"Dry mouth"},{"rate":"10-15","effect":"Paresthesia"},{"rate":"5-10","effect":"Cognitive impairment / memory issues"},{"rate":"5-10","effect":"Tachycardia"},{"rate":"5-10","effect":"Constipation"},{"rate":"5-10","effect":"Dizziness"}]},"_chembl":{"chemblId":"CHEMBL1574","moleculeType":"Small molecule","molecularWeight":"149.24"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Phentermine is a sympathomimetic amine that stimulates the release of norepinephrine in the hypothalamus, reducing appetite and increasing energy expenditure. Topiramate is an anticonvulsant that enhances weight loss through multiple mechanisms including increased satiety, reduced appetite, and potential metabolic effects. The combination produces synergistic weight loss effects beyond either agent alone.","oneSentence":"Phentermine acts as a sympathomimetic amine to suppress appetite, while topiramate enhances satiety and may increase metabolic rate through multiple mechanisms including carbonic anhydrase inhibition.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:50:53.652Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic weight management in obese or overweight patients with weight-related comorbidities"}]},"trialDetails":[{"nctId":"NCT04621929","phase":"PHASE3","title":"Phentermine/Topiramate for Uric Acid Stones","status":"COMPLETED","sponsor":"University of Florida","startDate":"2021-03-31","conditions":"Obesity, Uric Acid Stones, Type 2 Diabetes Mellitus in Obese","enrollment":19},{"nctId":"NCT05579249","phase":"PHASE4","title":"A Research Study Comparing Wegovy to Other Weight Management Drugs in People Living With Obesity in America","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2023-01-19","conditions":"Obesity","enrollment":500},{"nctId":"NCT07188545","phase":"","title":"Using Secondary Data to Evaluate Sex-based Heterogeneity of GLP-1 Agonists and SGLT2 Inhibitors on Cardiovascular-Kidney-Metabolic Health (CKMH) Outcomes in Real-world Settings (DASH-CKMH)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ohio State University","startDate":"2025-09-15","conditions":"Cardiovascular Kidney Metabolic Syndrome","enrollment":23280000},{"nctId":"NCT06299891","phase":"PHASE2","title":"Efficacy and Safety of Phentermine/Topiramate in Youth With Hypothalamic Obesity","status":"RECRUITING","sponsor":"Seattle Children's Hospital","startDate":"2025-03-01","conditions":"Hypothalamic Obesity, Hypothalamic Tumor, Craniopharyngioma","enrollment":24},{"nctId":"NCT04298203","phase":"PHASE2","title":"Role of Pharmacotherapy in Counteracting Weight Regain in Adolescents With Severe Obesity","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Minnesota","startDate":"2021-08-04","conditions":"Obesity","enrollment":100},{"nctId":"NCT04531176","phase":"PHASE4","title":"EMI-EHP Weight Management and Type 2 Diabetes Pragmatic Trial","status":"TERMINATED","sponsor":"The Cleveland Clinic","startDate":"2020-09-01","conditions":"Type 2 Diabetes, Obesity","enrollment":74},{"nctId":"NCT03374956","phase":"PHASE3","title":"Individualized Obesity Pharmacotherapy","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2017-12-11","conditions":"Obesity","enrollment":193},{"nctId":"NCT03799198","phase":"PHASE4","title":"Real World Effectiveness of Combining an Employer-based Weight Management Program With Medication for Chronic Weight Management in Employees With Obesity","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2019-01-07","conditions":"Obesity","enrollment":200},{"nctId":"NCT03922945","phase":"PHASE4","title":"A Phase IV Safety and Efficacy Study of VI-0521 in Adolescents With Obesity","status":"COMPLETED","sponsor":"VIVUS LLC","startDate":"2019-05-02","conditions":"Adolescent Obesity, Obesity in Adolescence, Adolescent Overweight","enrollment":223},{"nctId":"NCT00768404","phase":"PHASE1","title":"A Study to Evaluate the Pharmacokinetics of VI-0521 Subjects With Renal Impairment","status":"COMPLETED","sponsor":"VIVUS LLC","startDate":"2008-10","conditions":"Renal Impairment","enrollment":32}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Duromine","Adipex-P","Lomaira","Suprenza","Trokendi XR"],"phase":"phase_3","status":"active","brandName":"Phentermine / Topiramate Oral Product","genericName":"Phentermine / Topiramate Oral Product","companyName":"University of Florida","companyId":"university-of-florida","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Phentermine acts as a sympathomimetic amine to suppress appetite, while topiramate enhances satiety and may increase metabolic rate through multiple mechanisms including carbonic anhydrase inhibition. Used for Chronic weight management in obese or overweight patients with weight-related comorbidities.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}